Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer
JAMA · 18.04.2023 · 329 (15) · 1271
DOI: 10.1001/jama.2023.4428 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 18.04.2023. Verfasst von Jun Watanabe und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan. Hauptthemen laut MEDLINE: Bevacizumab, Antineoplastic Combined Chemotherapy Protocols, Panitumumab, Colorectal Neoplasms. Die Arbeit wurde bisher 289-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Importance For patients with RAS wild-type metastatic colorectal cancer, adding anti–epidermal growth factor receptor (anti-EGFR) or anti–vascular endothelial growth factor (anti-VEGF) monoclonal antibodies to first-line doublet chemotherapy is routine, but the optimal targeted therapy has not been defined.
Objective
To evaluate the effect of adding panitumumab (an anti-EGFR monoclonal antibody) vs bevacizumab (an anti-VEGF monoclonal antibody) to standard first-line chemotherapy for treatment of RAS wild-type, left-sided, metastatic colorectal cancer. Design, Setting, and Participants Randomized, open-label, phase 3 clinical trial at 197 sites in Japan in May 2015–January 2022 among 823 patients with chemotherapy-naive RAS wild-type, unresectable metastatic colorectal cancer (final follow-up, January 14, 2022).
Interventions
Panitumumab (n = 411) or bevacizumab (n = 412) plus modified fluorouracil, l -leucovorin, and oxaliplatin (mFOLFOX6) every 14 days. Main Outcomes and Measures The primary end point, overall survival, was tested first in participants with left-sided tumors, then in the overall population. Secondary end points were progression-free survival, response rate, duration of response, and curative (defined as R0 status) resection rate.
Results
In the as-treated population (n = 802; median age, 66 years; 282 [35.2%] women), 604 (75.3%) had left-sided tumors. Median follow-up was 61 months. Median overall survival was 37.9 months with panitumumab vs 34.3 months with bevacizumab in participants with left-sided tumors (hazard ratio [HR] for death, 0.82; 95.798% CI, 0.68-0.99; P = .03) and 36.2 vs 31.3 months, respectively, in the overall population (HR, 0.84; 95% CI, 0.72-0.98; P = .03). Median progression-free survival for panitumumab vs bevacizumab was 13.1 vs 11.9 months, respectively, for those with left-sided tumors (HR, 1.00; 95% CI, 0.83-1.20) and 12.2 vs 11.4 months overall (HR, 1.05; 95% CI, 0.90-1.24). Response rates with panitumumab vs bevacizumab were 80.2% vs 68.6%, respectively, for left-sided tumors (difference, 11.2%; 95% CI, 4.4%-17.9%) and 74.9% vs 67.3% overall (difference, 7.7%; 95% CI, 1.5%-13.8%). Median duration of response with panitumumab vs bevacizumab was 13.1 vs 11.2 months for left-sided tumors (HR, 0.86; 95% CI, 0.70-1.10) and 11.9 vs 10.7 months overall (HR, 0.89; 95% CI, 0.74-1.06). Curative resection rates with panitumumab vs bevacizumab were 18.3% vs 11.6% for left-sided tumors; (difference, 6.6%; 95% CI, 1.0%-12.3%) and 16.5% vs 10.9% overall (difference, 5.6%; 95% CI, 1.0%-10.3%). Common treatment-emergent adverse events were acneiform rash (panitumumab: 74.8%; bevacizumab: 3.2%), peripheral sensory neuropathy (panitumumab: 70.8%; bevacizumab: 73.7%), and stomatitis (panitumumab: 61.6%; bevacizumab: 40.5%). Conclusions and Relevance Among patients with RAS wild-type metastatic colorectal cancer, adding panitumumab, compared with bevacizumab, to standard first-line chemotherapy significantly improved overall survival in those with left-sided tumors and in the overall population. Trial Registration ClinicalTrials.gov Identifier: NCT02394795
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Immunology, Nagoya University Graduate School of Medicine, Aichi, Japan.
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
- Division of Gastrointestinal Surgery, Kanagawa Cancer Center, Kanagawa, Japan.
Zitieren
APA
Watanabe, J., Muro, K., Shitara, K., Yamazaki, K., Shiozawa, M., Ohori, H., Takashima, A., Yokota, M., Makiyama, A., Akazawa, N., Ojima, H., Yuasa, Y., Miwa, K., Yasui, H., Oki, E., Sato, T., Naitoh, T., Komatsu, Y., Kato, T., …, & Yoshino, T. (2023). Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer. JAMA, 329(15), 1271. https://doi.org/10.1001/jama.2023.4428
Vancouver
Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, et al. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer. JAMA. 2023;329(15):1271. doi:10.1001/jama.2023.4428
BibTeX
@article{Watanabe2023,
author = {Watanabe, Jun and Muro, Kei and Shitara, Kohei and Yamazaki, Kentaro and Shiozawa, Manabu and Ohori, Hisatsugu and Takashima, Atsuo and Yokota, Mitsuru and Makiyama, Akitaka and Akazawa, Naoya and Ojima, Hitoshi and Yuasa, Yasuhiro and Miwa, Keisuke and Yasui, Hirofumi and Oki, Eiji and Sato, Takeo and Naitoh, Takeshi and Komatsu, Yoshito and Kato, Takeshi and Hihara, Masamitsu and Soeda, Junpei and Misumi, Toshihiro and Yamamoto, Kouji and Akagi, Kiwamu and Ochiai, Atsushi and Uetake, Hiroyuki and Tsuchihara, Katsuya and Yoshino, Takayuki},
title = {Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer},
journal = {JAMA},
year = {2023},
volume = {329},
number = {15},
pages = {1271},
doi = {10.1001/jama.2023.4428}
}
EUVIMED